×
About 1,235 results

ALLMedicine™ Anticoagulation Center

Research & Reviews  426 results

Comparison of uninterrupted direct oral anticoagulation with vitamin-K antagonists duri...
https://doi.org/10.1002/clc.23676
Clinical Cardiology; Christoph M, Youssef A et. al.

Jul 28th, 2021 - Uninterrupted direct oral anticoagulation (DOAC) in AF-ablation is recommended, proven by randomized trials. The outcome and the periinterventional differences between DOACs and VKA in the real world clinical practice are discussed controversial. ...

Therapeutic anticoagulation after liver transplantation is not useful among patients wi...
https://doi.org/10.1111/jth.15472
Journal of Thrombosis and Haemostasis : JTH; Bos I, Blondeau M et. al.

Jul 24th, 2021 - Portal vein thrombosis (PVT) is no longer a contraindication for liver transplantation (LT). While therapeutic anticoagulation (tAC) is recommended during the waiting period, there is no evidence for its usefulness in the prevention of PVT recurre...

Early prophylactic anticoagulation after subarachnoid hemorrhage decreases systemic isc...
https://doi.org/10.1016/j.clineuro.2021.106809
Clinical Neurology and Neurosurgery; Hantsche A, Wilhelmy F et. al.

Jul 19th, 2021 - In neurosurgical perioperative treatment, especially in connection with subarachnoid hemorrhage (SAH), the prophylactic anticoagulation (AC) regimen is still considered controversial. The goal of this retrospective study was to assess how the time...

Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236305
Thrombosis Research; Rivera-Caravaca JM, Buckley BJR et. al.

Jul 5th, 2021 - It is unclear if direct-acting oral anticoagulants (DOACs) use before hospitalization due to COVID-19 diagnosis would potentially impact the severity and clinical outcomes thereafter. We compared 30-day hospitalization/re-hospitalization and clini...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  17 results

Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial Appendage Closure. (SWISS-APERO)
https://clinicaltrials.gov/ct2/show/NCT03399851

Feb 21st, 2020 - Non-valvular Atrial fibrillation (NVAF) is the most common cardiac arrhythmia and a major cause of morbidity and mortality because of cardioembolic stroke. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) or Non-vitamin K antagonist ant...

PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
https://clinicaltrials.gov/ct2/show/NCT00432796

Feb 19th, 2020 - There are a growing number of patients who receive long-term warfarin therapy for the prevention of arterial thromboembolism. The current approach to the perioperative management of anticoagulation (i.e. "bridging therapy") with low molecular weig...

Apixaban for Extended Anticoagulation (APIDULCIS)
https://clinicaltrials.gov/ct2/show/NCT03678506

Feb 5th, 2020 - This prospective cohort study aims to assess the efficacy and safety of a management procedure to decide on giving or not an extended anticoagulation (administering apixaban 2 2.5 mg twice daily ) to outpatients with a single episode of proximal d...

Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
https://clinicaltrials.gov/ct2/show/NCT03284827

Dec 17th, 2019 - This trial is to compare the efficacy of NOAC(Novel Oral Anticoagulants) with edoxaban vs. dual antiplatelet therapy (DAPT) for prevention of leaflet thrombosis (documented by cardiac CT imaging) and cerebral embolization (documented with brainDif...

Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
https://clinicaltrials.gov/ct2/show/NCT02592980

Jul 5th, 2019 - Investigators will recruit 300 patients with low TTR (<50%) from the Heart Institute- Clinical Hospital- University of São Paulo Medical School (InCor- HCFMUSP). The patients will be randomized into two groups: Traditional Anticoagulation (TA) gro...

see more →

News  50 results

Are Left Atrial Thrombi That Defy Preprocedure Anticoagulation Predictable?
https://www.medscape.com/viewarticle/952793

Jun 9th, 2021 - Three or more weeks of oral anticoagulation (OAC) sometimes isn't up to the job of clearing any potentially embolic left atrial (LA) thrombi before procedures like cardioversion or catheter ablation in patients with atrial fibrillation (AF). Such ...

Modest Clinical Gain for AF Screening of Asymptomatic Elderly: STROKESTOP
https://www.medscape.com/viewarticle/949950

Apr 26th, 2021 - Some, perhaps many, previously unrecognized cases of atrial fibrillation (AF) will come to light in a screening program aimed at older asymptomatic adults. The key question is whether the challenges of such systematic but age-restricted AF screeni...

Parity Whether Anticoagulation Is Halted or Not for Unplanned Cath
https://www.medscape.com/viewarticle/949064

Apr 9th, 2021 - Maintaining oral anticoagulation (OAC) throughout an unplanned cardiac catheterization confers no extra risk and might hold some advantages over periprocedural OAC interruption in patients on long-term anticoagulation therapy, suggests a major reg...

Left Atrial Appendage Occlusion, DOAC Comparable for AFib
https://www.medscape.com/viewarticle/944133

Jan 14th, 2021 - Left atrial appendage occlusion (LAAO) for high-risk atrial fibrillation seems to prevent stroke as well as direct oral anticoagulation (DOAC) with a lower risk of major bleeding, according to results of a European study. And although some experts...

'Low-Risk' Valvular AF in Some May be Risky Enough for Oral Anticoagulation
https://www.medscape.com/viewarticle/937294

Sep 11th, 2020 - Some patients with "valvular" atrial fibrillation (AF) and stroke-risk scores low enough for oral anticoagulation (OAC) not to be indicated may actually face enough thromboembolic risk to justify the lifelong therapy, a new report suggests. The co...

see more →